Greenlane and PAX Renew Distribution Agreement
PAX's award-winning portable dry herb cannabis vaporizers now more broadly available through Greenlane's distribution platform
BOCA RATON, FL / ACCESS Newswire Greenlane Holdings, Inc. ('Greenlane' or the 'Company') (NASDAQ:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced the renewal of its distribution agreement with PAX, a pioneer in the design and development of premium cannabis vaporization technologies and devices. The agreement maintains Greenlane's distribution throughout the U.S. for PAX's dry herb device portfolio, which includes the PAX MINI and PAX PLUS – New York Times Wirecutter's 2022, 2023 and 2024 pick for Best Portable Vaporizer.
PAX has long been recognized for its science-backed innovation, iconic design, and uncompromising commitment to quality-delivering clean, consistent, and elevated cannabis experiences for more than a decade. Through the reinvigoration of this relationship, PAX will be able to expand product access in key U.S. markets through Greenlane's strong retail network, operational scale, and deep industry relationships. Together, both companies share a vision for high-quality products, responsible growth, and a thriving, consumer-centric cannabis industry.
'Cannabis vaporizers continue to be a growing market, and PAX offers an extensive line of unique award-winning devices and a high performing team that has built a loyal and growing consumer base. We look forward to continuing our long-standing collaboration with PAX, a relationship that significantly enriches and compliments our distinguished portfolio of brands and partners,' said Barbara Sher, Chief Executive Officer for Greenlane.
'We're thrilled to re-energize our partnership with Greenlane, a company that's been a trusted collaborator in the cannabis accessory space for years,' said Francois Nadon, Head of Global Wholesale at PAX. 'As we prepare to launch some of our most exciting innovations yet, this year and beyond, Greenlane's scale and retail reach will help us ensure more consumers can access the high-quality experience PAX is known for.'
About PAX
PAX is a leading global cannabis brand on a mission to enhance people's lives, honoring the power of the plant through pioneering innovation, peerless quality and premium design. For more than a decade, PAX has delivered high-performance products-crafted for precision, purity and consistency-that are trusted by millions. PAX is committed to making a positive impact and has been recognized by The New York Times' Wirecutter, TIME, Fast Company, GQ, Gear Patrol, High Times, and more. PAX, designed for those who aim higher.
About Greenlane Holdings, Inc.
Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform.
We proudly offer our own diverse brand portfolio and our exclusively licensed Marley Natural and K.Haring branded products. We also offer a carefully curated set of third-party products through our direct sales channels and our proprietary, owned and operated e-commerce platforms which include Vapor.com, , PuffItUp.com, HigherStandards.com, Wholesale.Greenlane.com and MarleyNaturalShop.com.
Investor Contact:
IR@greenlane.com
or
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Greenlane and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'could,' 'intends,' 'targets,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Greenlane has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission ('SEC'), including under the caption 'Risk Factors' in Greenlane's Annual Report on Form 10-K filed for the year ended December 31, 2023 and the Company's other filings with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.
SOURCE: Greenlane Holdings, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Why Palantir Technologies Hit a New All-Time High on Wednesday
One Wall Street analyst boosted Palantir's price target, despite maintaining a sell rating. The reasoning for the move was decidedly bullish. The key factor in the rating is Palantir's frothy valuation. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock continued its epic run on Wednesday, climbing as much as 5.4%. As of 3:37 p.m. ET, the stock was still up 3%. The artificial intelligence (AI) software and data mining specialist has climbed to new heights several times in recent weeks, with its stock notching a new all-time high on Wednesday. That puts the stock up more than 80% so far this year. The catalyst behind today's move was a reluctant nod from a Wall Street analyst. Mizuho analyst Matthew Broome kept an underperform (sell) rating on Palantir stock, but raised his price target for Palantir to $116, up from its previous level of $94. For those keeping score at home, that's roughly 12% below the stock's closing price on Tuesday, so the analyst is obviously playing catch-up. Broome cited Palantir's "strong recent execution and significant upward revisions" for his price target increase. The analyst also noted the company's "strong strategic positioning with large customers and potential for further accelerated growth in future years." So, if the analyst is so bullish on Palantir, why maintain the sell rating? In a word: valuation. Palantir stock is currently selling for 594 times earnings and 109 times sales. With multiples of that magnitude, it isn't for the faint of heart. Even factoring in the company's accelerating growth, it sports a price-to-earnings growth (PEG) ratio of 6, when any number higher than 1 is overvalued. Don't get me wrong: I'm a dyed-in-the-wool Palantir bull. However, valuation is a fickle mistress, and any failure by the company to execute -- real or perceived -- could bring the stock crashing down. In fact, I wouldn't be surprised to see Palantir stock get cut in half at some point over the next year -- before climbing to even greater heights. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Danny Vena has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Why Palantir Technologies Hit a New All-Time High on Wednesday was originally published by The Motley Fool
Yahoo
39 minutes ago
- Yahoo
‘Global arms race with artificial intelligence': TN rep. supports xAI project moving forward
MEMPHIS, Tenn. — A state representative from Memphis says he supports Elon Musk's xAI, and says the company is planning up to eight more sites in the area. Republican state Rep. John Gillespie's comments came after state representatives had a press conference on Tuesday against the project moving forward. 'Why is economic development always at the cost of poor folk? Always at the cost of low wel people? We as a city have to have higher self-esteem, we as a city have to believe better about who we are,' said State Rep. Justin J. Pearson, (D-Memphis). Pearson and other democratic lawmakers met with Memphis Mayor Paul Young on Tuesday. Republican Rep. John Gillespie (R-Memphis) says he was there too, and he has a different take on xAI. Memphis mayor meets with state leaders over xAI concerns 'I'm extremely excited and the potential of all the other things that will follow,' said Gillespie. 'We're in a global arms race with artificial intelligence.' 'We're competing not with Silicon Valley, but we're actually competing with China and Russia, and North Korea. xAI and people at xAI have said that they plan on winning that arms race,' said Gillespie. In a statement, he talked about the large amount of tax dollars the company brings also saying, 'Hundreds of Memphians are currently working in construction as xAI plans to build on at least eight sites in Shelby County. ' Rep. Justin Pearson, NAACP aim to halt xAI project in Memphis 'Right now if you do look up, xAI has four sites right now that they have and they've publicly said more are to come. I don't know how many that number is, I hope it's more than eight but I suspect it will be more than eight as well,' said Gillespie. 'Well the data that I've seen and the health department has confirmed and the manufacturer of the turbines have also confirmed, they have technology on there that makes it no more than a dry cleaning or a gas station,' said Gillespie. Mayor Paul Young said there are plans to bring more community-based testing of the air quality in the area of xAI. 'My goal is to make sure our people are protected from a health perspective and that we use this project to boost our city economically,' said Mayor Young. Gillespie says he's all for the testing. It's unclear when that testing will be happening in southwest Memphis and the Boxtown community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
